

A Distinct Nasal Microbiota Signature in Peritoneal Dialysis Patients

Iman Khan¹, Sylvia Wu¹, Anika Hudson¹, Clayton Hughes¹, Gabriel Stryjniak¹, Lars F. Westblade^{2,3}, Michael J. Satlin^{2,3}, Nicholas Tedrow¹, Anne-Catrin Uhlemann⁴, Colleen Kraft⁵, Darshana M. Dadhania^{1,6}, Jeffrey Silberzweig^{1,7}, Iwijn De Vlaminck⁸, Carol Li¹, Vesh Srivatana^{1,7*}, John Richard Lee^{1,6*}

1. Division of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medicine, New York, NY, USA

2. Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA

3. Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY, USA

4. Division of Infectious Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons Columbia University, New York, NY

5. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, New York, NY

6. Department of Transplantation Medicine, New York Presbyterian Hospital–Weill Cornell Medical Center, New York, NY, USA

7. The Rogosin Institute, New York, NY, USA

8. Department of Biomedical Engineering, Cornell University, Ithaca, NY, USA

Abstract word count: 299

Manuscript body word count: 2938

* V.S. and J.R.L. contributed equally to this work

Correspondence to Dr. Vesh Srivatana, ves2009@nyp.org, or Dr. John R. Lee, jrl2002@med.cornell.edu

26 **Authors' Contributions.** IK, ACH, VS, and JRL designed the study. IK, VS, and JRL collected
27 samples and clinical metadata. AH, CH, and CL processed specimens and performed experiments.
28 IK, SW, GS, LFW, MJS, NT, ACH, CK, DMD, JS, VS, IDV, and JRL collected and analyzed
29 data. IK, SW, GS, LFW, MJS, ACH, CK, DMD, JS, IDV, VS, and JRL wrote the manuscript. All
30 authors read and approved the final manuscript.

31

32 **Funding.** This study was supported in part by R21AI164093 (JRL, IDW).

33

34 **Financial Disclosure.** DMD, JRL, and IDV hold patent US-2020-0048713-A1 titled “Methods
35 of Detecting Cell-Free DNA in Biological Samples” licensed to Eurofins Viracor. LFW has
36 received or receives research support from Accelerate Diagnostics, Inc., bioMérieux, Inc., Hardy
37 Diagnostics, and Roche Molecular Systems, Inc., and consulting fees from Roche Molecular
38 Systems, Inc., Shionogi, Inc., and Talis Biomedical. MJS reports research support from Merck,
39 Biomérieux, and SNIPRBiome, compensation for consulting from Shionogi, and compensation
40 for participation in a Data and Safety Monitoring Board from AbbVie. CK is a consultant for
41 Rebiotix/Ferring and on the Scientific Advisory Board of Seres Therapeutics. DMD serves as a
42 consultant for CareDx and is a site clinical investigator for studies sponsored by AlloVir and
43 CSL Behring. JS is the Co-Chair of the American Society of Nephrology Workgroup on
44 COVID-19 and other Emerging Threats and of the American Society of Nephrology Emergency
45 Partnership Initiative and has received consulting fees from Alkahest, Bayer, Honeywell, Kaneka
46 and St. Gobain. IDV is a member of the Scientific Advisory Board of Karius Inc., Kanvas
47 Biosciences and GenDX. VS reports receiving speakers' fees from Baxter Healthcare. JRL

48 received research support under an investigator-initiated research grant from BioFire

49 Diagnostics, LLC. JRL receives speakers' fees from Astellas.

50

51 **Acknowledgments.** We thank Dr. Manikkam Suthanthiran for his overall guidance in this

52 project.

53

54

ABSTRACT

55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77

Rationale & Objective. The nasal passages harbor both commensal and pathogenic bacteria. In this study, we sought to characterize the anterior nasal microbiota in PD patients using 16S rRNA gene sequencing.

Study Design. Cross-sectional.

Setting & Participants. We recruited 32 PD patients, 37 kidney transplant (KTx) recipients, 22 living donor/healthy control (HC) participants and collected anterior nasal swabs at a single point in time.

Predictors. We performed 16S rRNA gene sequencing of the V4-V5 hypervariable region to determine the nasal microbiota.

Outcomes. Nasal microbiota profiles were determined at the genus level as well as the amplicon sequencing variant level.

Analytical Approach. We compared nasal abundance of common genera among the 3 groups using Wilcoxon rank sum testing with Benjamini-Hochberg adjustment. DESeq2 was also utilized to compare the groups at the ASV levels.

Results. In the entire cohort, the most abundant genera in the nasal microbiota included:

Staphylococcus, *Corynebacterium*, *Streptococcus*, and *Anaerococcus*. Correlational analyses revealed a significant inverse relationship between the nasal abundance of *Staphylococcus* and that of *Corynebacterium*. PD patients have a higher nasal abundance of *Streptococcus* than KTx recipients and HC participants. PD patients have a more diverse representation of *Staphylococcus* and *Streptococcus* than KTx recipients and HC participants. PD patients who concurrently have or who developed future *Staphylococcus* peritonitis had a numerically higher

78 nasal abundance of *Staphylococcus* than PD patients who did not develop *Staphylococcus*
79 peritonitis.

80 **Limitations.** 16S RNA gene sequencing provides taxonomic information to the genus level.

81 **Conclusions.** We find a distinct nasal microbiota signature in PD patients compared to KTx
82 recipients and HC participants. Given the potential relationship between the nasal pathogenic
83 bacteria and infectious complications, further studies are needed to define the nasal microbiota
84 associated with these infectious complications and to conduct studies on the manipulation of the
85 nasal microbiota to prevent such complications.

86

87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109

INTRODUCTION

The anterior nasal microbiota is at the interface between the external environment and the nasal passages and contains a combination of commensal and pathogenic bacteria. The most common genera defined in healthy individuals in the Human Microbiome Project are *Staphylococcus*, *Corynebacterium*, *Propionibacterium*, and *Moraxella* (1). Subsequent studies on the nasal microbiota have revealed microbiota dysbiosis in diseased states such as chronic rhinosinusitis (2) and have linked the nasal microbiota to infectious complications after elective surgical procedures (3).

Peritoneal dialysis (PD) patients undergo dialysis through PD catheter through their abdomen. Despite being taught sterile technique, PD patients experience both exit site infections around the catheter and infectious peritonitis. Prior work has established that pathogenic bacteria in the nasal passages may be associated with infectious complications in PD patients. Luzar et al. reported that *Staphylococcus aureus* nasal colonization was associated with exit site infections in a cohort of 140 PD patients (4). Other studies have found that persistent nasal colonization with *S. aureus* was also associated with peritonitis (5, 6). Decolonization with mupirocin has been suggested to prevent infections and the MUPIROCIN Study Group found that nasal mupirocin prevented *S. aureus* exit site infection (7). Despite these data, International Society of Peritoneal Dialysis (ISPD) guidelines do not support the routine use of nasal mupirocin (8).

Because no study to date has comprehensively evaluated the anterior nasal microbiota in PD patients, we performed a pilot study to evaluate the anterior nasal microbiota using 16S rRNA

110 gene sequencing of the V4-V5 hypervariable region in PD patients, in kidney transplant
111 recipients, and healthy controls.

112

113 **METHODS**

114

115 *Study Cohort Recruitment and Nasal Swab Specimen Collection*

116

117 From August 2021 to January 2022, we recruited patients receiving peritoneal dialysis (PD),
118 kidney transplant (KTx) recipients, and living donor/healthy control (HC) participants for
119 anterior nasal swab specimen collection. All kidney transplant recipients and living donor
120 candidates were recruited from the clinic. Most PD patients were recruited in the PD clinic;
121 several were recruited during hospitalization. The Weill Cornell Institutional Review Board
122 approved this protocol (IRB # 1604017181) and all participants provided written informed
123 consent.

124

125 Anterior nasal swab specimens were collected once from each participant using the Human
126 Microbiome Project protocol. A Copan Eswab (Copan Diagnostics, Murietta, CA, USA) was
127 inserted into the anterior part of one nostril of the participant and turned twice and was then
128 inserted into the anterior part of the other nostril and turned twice. The Copan Eswab was then
129 placed into 1 mL of liquid Amies provided by the Copan Eswab technology and immediately
130 stored on ice or 4°C. Aliquots of 300 uL were created in 2 mL cryovial and stored at -80°C
131 within 12 hours.

132

133 ***16S rRNA gene sequencing of the V4-V5 hypervariable region***

134

135 A single aliquot of approximately 285 μ L was deposited into a Qiagen PowerBead glass 0.1 mm
136 tube. Using a Promega Maxwell RSC PureFood GMO and Authentication Kit (AS1600), 1mL of
137 CTAB buffer & 20 μ L of RNase A Solution was added to the PowerBead tube containing the
138 sample. The sample/buffer was mixed for 10 seconds on a Vortex Genie2 and then incubated at
139 95°C for 5 minutes on an Eppendorf ThermoMixer F2.0, shaking at 1500 rpm. The tube was
140 removed and clipped to a horizontal microtube attachment on a Vortex Genie2 (SI-H524) and
141 vortexed at high-speed for 20 minutes. The sample was removed from the Vortex and
142 centrifuged on an Eppendorf Centrifuge 5430R at 40°C, 12700 rpm for 10 minutes. Upon
143 completion, the sample was centrifuged again for an additional 10 minutes to eliminate foam.
144 The tube was then added to a Promega MaxPrep Liquid Handler tube rack. The Liquid Handler
145 instrument was loaded with proteinase K tubes, lysis buffer, elution buffer, 1000mL tips, 50mL
146 tips, 96-sample deep-well plate, and Promega Maxwell RSC 48 plunger tips. The Promega
147 MaxPrep Liquid Handler instrument was programmed to use 300 μ L of sample and transfer all
148 sample lysate into Promega Maxwell RSC 48 extraction cartridge for DNA extraction. Upon
149 completion, the extraction cartridge was loaded into Promega Maxwell RSC 48 for DNA
150 extraction & elution. DNA was eluted in 100 μ L and transferred to a standard 96-well plate.
151 DNA was quantified using Quant-iT dsDNA High Sensitivity Assay Kit using Promega GloMax
152 plate reader on a microplate (655087). 16S rRNA library generation followed the protocol from
153 the Earth Microbiome Project.

154

155 Amplicon libraries were washed using Beckman Coulter AMPure XP magnetic beads. Library
156 quality & size verification was performed using PerkinElmer LabChip GXII instrument with
157 DNA 1K Reagent Kit (CLS760673). Library concentrations were quantified using Quant-iT
158 dsDNA High Sensitivity Assay Kit using Promega GloMax plate reader on a microplate
159 (655087). Library molarity was calculated based on library peak size & concentration. Libraries
160 were normalized to 2nM using the PerkinElmer Zephyr G3 NGS Workstation (133750) and
161 pooled together using the same volume across all normalized libraries into a 1.5mL Eppendorf
162 DNA tube (022431021). Sequencing was performed on an Illumina MiSeq instrument at loading
163 concentration of 7 pM with 15% PhiX, paired-end 250 using MiSeq Reagent Kit v2, 500-cycles
164 (MS-102-2003).

165

166 *Bioinformatics Pipeline*

167

168 Demultiplexed raw reads were processed using the Nextflow (9) nf-core (10) ampliseq pipeline
169 (11), version 2.2.0, with the following parameters: `--profile singularity --input SampleSheet.tsv --`
170 `FW_primer GTGYCAGCMGCCGCGGTAA --RV_primer CCGYCAATTYMTTTRAGTTT --`
171 `metadata Metadata.tsv --outdir results --dada_ref_taxonomy silva --ignore_empty_input_files --`
172 `ignore_failed_trimming --min_frequency 10 --retain_untrimmed --truncLenf 240 --truncLenr 160.`

173 Specifically, reads were trimmed with cutadapt (12), PhiX and quality filtering, read pair
174 merging, and amplicon sequence variant resolution was performed with DADA2 (13).

175 Subsequent taxonomic assignment was also performed with DADA2, using the Silva reference
176 database (14), version 138. Sequences that were assigned the families, Chloroplast and
177 Mitochondria, were removed from downstream analyses.

178

179 ***Biostatistical Analyses***

180

181 The distribution of categorical variables were compared using Fisher’s exact tests. The
182 distribution of continuous variables were compared using Wilcoxon rank sum tests and to
183 account for the comparison of multiple taxa, adjusted p values were calculated using Benjamini-
184 Hochberg adjustment for multiple comparisons. DESeq2 was utilized to detect differences at the
185 ASV between the groups using Benjamini-Hochberg adjustment. Comparison of correlations
186 using a correlational matrix was adjusted for multiple comparisons using the Bonferonni method.
187 All statistical tests were performed using R 4.1.3 in RStudio.

188

189 ***Data Availability***

190 Sequencing data that support the findings of this study will be made available in the database of
191 Genotypes and Phenotypes (dbGaP) phs002251.v1.p1 after peer-reviewed acceptance. Local
192 institutional review board approval will be needed to access the data.

193

194

RESULTS

195

196 ***Characteristics of the Study Cohort and Nasal Microbial Sequencing***

197

198 The microbiota in the anterior nares was performing using 16S rRNA gene sequencing of the
199 V4-V5 hypervariable region in 32 PD patients, 37 KTx recipients, 22 HC participants, and 3
200 negative controls. A total of 1,116,291 reads with assigned taxonomy was obtained in the cohort

201 of 91 participants with a median of 12,713 assigned reads with an interquartile range of 7,132
202 and 16,018 assigned reads. The number of assigned reads in the 3 negative controls were 146,
203 308, and 529, below the number in the cohort of participants.

204

205 Table 1 shows the demographics of the participants. In general, the PD patients were older than
206 the HC participants and similar in age to the KTx recipients. More than 50% of PD patients
207 performed automated peritoneal dialysis and 15% had current *Staphylococcus* peritonitis or
208 developed future *Staphylococcus* peritonitis within 10 to 12 months from the nasal specimen
209 collection (last follow up). Approximately a third of KTx recipients received deceased donor
210 transplantation and 32% were on trimethoprim/sulfamethoxazole (TMP-SMX) prophylaxis.

211

212 ***Anterior Nasal Microbial Diversity Differs Across the Study Cohort***

213

214 Microbial diversity among the study participants was measured at the ASV level using the
215 Shannon diversity, an index that evaluates the richness and evenness in a community, as well as
216 Chao1, an index that estimates the total number of ASVs in the specimens. Fig. 1A and B show
217 box and whisker plots of these diversity indices and reveal that PD patients had a significantly
218 higher Shannon diversity index and Chao1 diversity index than KTx recipients ($P < 0.05$,
219 Wilcoxon rank sum test) but similar to the HC participants ($P > 0.05$).

220

221 ***Staphylococcus* Abundance Negatively Correlates with *Corynebacterium* Abundance in**

222 **Anterior Nasal Specimens**

223

224 We further evaluated the anterior nasal microbiota among the study cohort at the genus level. At
225 the genus level, the top abundant genera (>1% mean abundance across the cohort) included
226 *Staphylococcus*, *Corynebacterium*, *Anaerococcus*, *Streptococcus*, unspecified *Neisseriaceae*,
227 *Moraxella*, *Cutibacterium*, *Peptoniphilus*, and *Finegoldia* (Fig. 2A). We performed a
228 correlational matrix analysis among each of the genera (Fig. 2B). The relative abundance of
229 *Staphylococcus* was inversely correlated with that of *Corynebacterium* (Pearson $r = -0.66$,
230 adjusted P value < 0.10, Benjamini-Hochberg adjustment). The relative abundances of
231 *Peptoniphilus* was positively associated with that of *Anaerococcus* ($r=0.52$, adjusted P value <
232 0.10) and of *Finegoldia* ($r=0.27$, adjusted P value < 0.10). The relative abundance of *Finegoldia*
233 was positively associated with that of *Anaerococcus* ($r= 0.60$, adjusted P value < 0.10). The
234 relative abundance of Unspecified *Neisseriaceae* was positively associated with that of
235 *Cutibacterium* ($r= 0.31$, adjusted P value < 0.10).

236

237 ***Distinct Anterior Nasal Microbiota Define PD Patients and Kidney Transplant Recipients***

238

239 The individual profiles of the top genera in anterior nasal microbiota are shown in the PD
240 patients, KTx recipients, and HC participants (Fig. 3). Fig. 4 shows box and whisker plots of the
241 top 9 taxa among the PD patients, the KTx recipients, and the HC participants and Table 2 shows
242 the comparisons among the groups using Wilcoxon rank sum testing with Benjamini-Hochberg
243 adjustment. PD patients had a distinctly higher relative abundance of *Streptococcus* than KTx
244 recipients or HC participants (Adjusted P value < 0.10, Wilcoxon rank sum test, Benjamini-
245 Hochberg adjustment) (Fig. 4D). PD patients also had lower abundance of unspecified
246 *Neisseriaceae*, *Moraxella*, *Cutibacterium*, and *Peptoniphilus* than HC participants (Fig. 4G)

247 (Adjusted P value < 0.10). Kidney transplant recipients had a lower abundance of *Moraxella* than
248 HC participants (Adjusted P value < 0.10). Other than *Streptococcus*, KTx recipients had similar
249 abundance of the top genera compared to PD patients (Adjusted P value > 0.10).

250

251 In order to gain further insight, we evaluated the taxa at the ASV level. We performed pairwise
252 DESeq2 between the groups to identify ASVs that were consistently different among the groups.
253 Fig. 5 shows the significant log₂ fold abundance changes between the groups and SI Tables 1 to
254 3 reveal the changes in the nasal abundances of the groups. Both PD patients and KTx recipients
255 had significantly higher nasal abundances of *Staphylococcus* ASV #1 and *Corynebacterium* ASV
256 #1 and lower abundance of *Anaerococcus* ASV #1 than HC participants (Adjusted p value <
257 0.10, Benjamini-Hochberg adjustment). PD patients had higher nasal abundance of
258 *Staphylococcus* ASV #2, *Abiotrophia* ASV #1, and *Porphyromonas* ASV #1 than KTx
259 recipients or HC participants (Adjusted p value < 0.10).

260

261 ***PD Patients Have a More Diverse Representation of Staphylococcus and Streptococcus than***
262 ***KTx Recipients and HC Participants***

263

264 To further understand why PD patients have higher microbial diversity, we evaluated the
265 diversity of ASVs in the most common genera: *Staphylococcus*, *Corynebacterium*, and
266 *Streptococcus*. There were 61 different *Staphylococcus* ASVs identified in the whole cohort. PD
267 patients had a significantly higher number of *Staphylococcus* ASVs per specimen than KTx
268 patients (P=0.03, Wilcoxon rank sum test) and HC participants (P=0.04). There were 95 different
269 *Corynebacterium* ASVs identified in the whole cohort. PD patients, KTx patients, and HC

270 participants had similar number of *Corynebacterium* ASVs per specimen ($P>0.10$). There were
271 46 different *Streptococcus* ASVs identified in the whole cohort. PD patients had a significantly
272 higher number of *Streptococcus* ASVs per specimen than KTx patients ($P=0.04$) and HC
273 participants ($P=0.05$).

274

275 ***Clinical Factors, Outcomes, and the Nasal Microbiota***

276

277 We next evaluated the relationship among the nasal microbiota, clinical factors, and outcomes in
278 the cohort. There were no significant differences in the nasal abundances of the most common
279 genera based upon age greater than or equal to 65 years old (SI Table 4). The relative abundance
280 of *Peptoniphilus* was significantly higher in male patients than in female patients (adjusted P
281 value < 0.10) (SI Table 5). Twelve of the kidney transplant recipients were on TMP-SMX
282 prophylaxis for *Pneumocystic jirovecii* prophylaxis and 35 were not. There were no significant
283 differences in the nasal abundance of the most common genera between the kidney transplant
284 recipients on TMP-SMX and those who were not (SI Table 6). In the PD cohort, 6 PD patients
285 concurrently had *Staphylococcus* peritonitis or developed future *Staphylococcus* peritonitis
286 within 10 to 12 months (last follow up) (Staph Peritonitis Group) and 26 PD patients did not (No
287 Staph Peritonitis Group). The nasal abundance of *Staphylococcus* was higher in the Staph
288 Peritonitis Group than in the No Staph Peritonitis Group but the difference was not statistically
289 significant (median abundance 52% vs. 24%, respectively, adjusted P value 0.73). There were no
290 significant differences in the nasal abundance of the other most common genera between the
291 *Staph* Peritonitis Group and the No *Staph* Peritonitis Group (SI Table 7).

292

293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315

DISCUSSION

This study aimed to describe the anterior nasal microbiota across different groups of patients with kidney disease. We detect a distinct microbial signature in the anterior nares of PD patients compared to KTx recipients and HC participants.

Many of the most common genera in the kidney cohort overlap with those reported in healthy individuals and include *Staphylococcus*, *Corynebacterium*, *Finnegoldia*, and *Cutibacterium* (15, 16). However, there were some distinct differences among the groups. PD patients had a higher nasal abundance of *Streptococcus* than HC participants or KTx recipients. Interestingly, having a higher nasal abundance of *Streptococcus* has been associated with respiratory infections such as bronchiolitis in infants (17). While the most common type of infectious peritonitis is *Staphylococcus* in origin, *Streptococcus* peritonitis also occurs in PD patients. Our study was not able to directly address whether PD patients with nasal abundance of *Streptococcus* is associated with *Streptococcus* peritonitis and/or respiratory viral infections, but such a link would provide the groundwork for novel approaches to manipulate the nasal microbiota to prevent such complications.

In our analysis, we noticed a higher nasal microbial diversity in the PD patients compared to KTx recipients and HC participants. Further analysis showed that part of this increased microbial diversity may be due to a more diverse representation of *Staphylococcus* and *Streptococcus* in PD patients (Fig. 6). This may have interesting implications as prior data suggests that PD patients with *Staphylococcus aureus* colonization had a higher incidence of exit site infections

316 (Ref). In our study, we did find an increased nasal abundance of *Staphylococcus* in PD patients
317 who had a history of *Staphylococcus* peritonitis and/or developed *Staphylococcus* peritonitis.
318 While the association was not significant, it could be due to the low number of PD patients in the
319 PD Staph peritonitis as our study was not powered to detect the differences. At the 16S rRNA
320 level, we were not able to determine *Staphylococcus* at the species level and this limitation
321 prevented us to assess this association in more detail.

322
323 Our data also highlight a strong inverse association between the nasal abundance of
324 *Staphylococcus* and that of *Corynebacterium*. Interesting mechanistic studies have shown a
325 complicated relationship between these two taxa, which represent the most common taxa in the
326 nasal microbiota. One study found that *Corynebacterium* species can secrete antimicrobial
327 peptides against *Staphylococcus aureus* (18). Another study has shown that *Corynebacterium*
328 species can decrease the virulence of *S. aureus* (19). Taken together, our data are consistent with
329 the inverse relationship and suggest potential novel approaches to manipulate the nasal
330 microbiota. For example, since *Staphylococcus* peritonitis is much more common than
331 *Corynebacterium* peritonitis, establishing a *Corynebacterium* dominant nasal microbiota may be
332 preventative of *Staphylococcus* in the nasal passages and possibly decrease the risk for
333 *Staphylococcus* exit site infection and/or peritonitis.

334
335 A surprising result is that we did not find an association between the TMP/SMX and nasal
336 microbiota differences. TMP/SMX has broad coverage against gram positive cocci including
337 *Staphylococcus* species. There are few studies which have investigated the role of oral antibiotics
338 on the nasal microbiota and it is possible that intra-nasal antibiotics rather than oral antibiotics

339 may more efficiently impact the nasal microbiota. While our study is limited by the population
340 size and the cross-sectional nature, our study raises this possibility.

341
342 There are several limitations to our study. As mentioned prior, we are unable to assess species
343 level identification via 16S rRNA gene sequencing of the V4-V5 hypervariable region. Future
344 studies using whole gene 16S rRNA gene sequencing or metagenomic sequencing may provide
345 better resolution on the intricate intra-species competition between the microbiota, particularly
346 between *Staphylococcus* species. and *Corynebacterium* species. Given the low biomass of the
347 nasal microbiota, environmental contamination and/or contamination through the DNA
348 processing steps could artificially introduce microbiota in our specimens. However, we did
349 sequence negative controls (Fig. 3) and the most abundant microbiota identified were not the
350 most common nasal microbiota flora previously reported, suggesting that the nasal microbiota
351 identified in our cohort was present in higher quantities and distinct. The cross-sectional nature
352 of our study provides a snapshot of the microbiota across different groups of patients with kidney
353 disease but does not provide longitudinal changes. Such a longitudinal study may provide more
354 insight into the relationship between the microbiota and clinical factors and outcomes in the
355 populations.

356
357 In conclusion, we provide the first description of a distinct nasal microbiota signature in PD
358 patients compared to KTx recipients and HC participants. We find a higher abundance of
359 *Streptococcus* and a more diverse representation of *Staphylococcus* and *Streptococcus* in PD
360 patients. Given the potential relationship between the nasal bacteria and infectious complications
361 in PD patients, further studies are needed to define the nasal microbiota associated with these

362 infectious complications and to conduct studies on the manipulation of the nasal microbiota to

363 prevent such complications.

364

365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385

REFERENCES

1. Human Microbiome Project C. Structure, function and diversity of the healthy human microbiome. *Nature*. 2012;486(7402):207-14.
2. Chen F, Gao W, Yu C, Li J, Yu F, Xia M, et al. Age-Associated Changes of Nasal Bacterial Microbiome in Patients With Chronic Rhinosinusitis. *Front Cell Infect Microbiol*. 2022;12:786481.
3. Hsiao CJ, Paulson JN, Singh S, Mongodin EF, Carroll KC, Fraser CM, et al. Nasal Microbiota and Infectious Complications After Elective Surgical Procedures. *JAMA Netw Open*. 2021;4(4):e218386.
4. Luzar MA, Coles GA, Faller B, Slingeneyer A, Dah GD, Briat C, et al. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. *N Engl J Med*. 1990;322(8):505-9.
5. Nouwen JL, Fieren MW, Snijders S, Verbrugh HA, and van Belkum A. Persistent (not intermittent) nasal carriage of Staphylococcus aureus is the determinant of CPD-related infections. *Kidney Int*. 2005;67(3):1084-92.
6. Ong LM, Ch'ng CC, Wee HC, Supramaniam P, Zainal H, Goh BL, et al. Risk of Peritoneal Dialysis-Related Peritonitis in a Multi-Racial Asian Population. *Perit Dial Int*. 2017;37(1):35-43.
7. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. Mupirocin Study Group. *J Am Soc Nephrol*. 1996;7(11):2403-8.

- 386 8. Li PK, Szeto CC, Piraino B, de Arteaga J, Fan S, Figueiredo AE, et al. ISPD Peritonitis
387 Recommendations: 2016 Update on Prevention and Treatment. *Perit Dial Int.*
388 2016;36(5):481-508.
- 389 9. Di Tommaso P, Chatzou M, Floden EW, Barja PP, Palumbo E, and Notredame C. Nextflow
390 enables reproducible computational workflows. *Nat Biotechnol.* 2017;35(4):316-9.
- 391 10. Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework
392 for community-curated bioinformatics pipelines. *Nat Biotechnol.* 2020;38(3):276-8.
- 393 11. Straub D, Blackwell N, Langarica-Fuentes A, Peltzer A, Nahnsen S, and Kleindienst S.
394 Interpretations of Environmental Microbial Community Studies Are Biased by the
395 Selected 16S rRNA (Gene) Amplicon Sequencing Pipeline. *Front Microbiol.*
396 2020;11:550420.
- 397 12. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing
398 reads. *EMBnetjournal.* 2011;17:<https://doi.org/10.14806/ej.17.1.200>.
- 399 13. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, and Holmes SP. DADA2: High-
400 resolution sample inference from Illumina amplicon data. *Nat Methods.* 2016;13(7):581-
401 3.
- 402 14. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal
403 RNA gene database project: improved data processing and web-based tools. *Nucleic*
404 *Acids Res.* 2013;41(Database issue):D590-6.
- 405 15. Oh J, Conlan S, Polley EC, Segre JA, and Kong HH. Shifts in human skin and nares
406 microbiota of healthy children and adults. *Genome Med.* 2012;4(10):77.

- 407 16. Pereira PAB, Aho VTE, Paulin L, Pekkonen E, Auvinen P, and Scheperjans F. Oral and
408 nasal microbiota in Parkinson's disease. *Parkinsonism Relat Disord*. 2017;38:61-7.
- 409 17. Hasegawa K, Linnemann RW, Mansbach JM, Ajami NJ, Espinola JA, Petrosino JF, et al.
410 Nasal Airway Microbiota Profile and Severe Bronchiolitis in Infants: A Case-control
411 Study. *Pediatr Infect Dis J*. 2017;36(11):1044-51.
- 412 18. Menberu MA, Liu S, Cooksley C, Hayes AJ, Psaltis AJ, Wormald PJ, et al. *Corynebacterium*
413 *accolens* Has Antimicrobial Activity against *Staphylococcus aureus* and Methicillin-
414 Resistant *S. aureus* Pathogens Isolated from the Sinonasal Niche of Chronic
415 Rhinosinusitis Patients. *Pathogens*. 2021;10(2).
- 416 19. Ramsey MM, Freire MO, Gabriliska RA, Rumbaugh KP, and Lemon KP. *Staphylococcus*
417 *aureus* Shifts toward Commensalism in Response to *Corynebacterium* Species. *Front*
418 *Microbiol*. 2016;7:1230.
- 419
420

421

TABLE 1

Characteristic	PD Cohort (n=32) median abundance	KTx Cohort (n = 37) median abundance	HC Cohort (n = 22) median abundance
Age, years	63 (51, 73)	59 (52, 67)	51 (33, 61)
Female Sex	20 (63%)	17 (46%)	13 (59%)
Ethnicity			
Hispanic	3 (9%)	2 (5%)	3 (14%)
Non-Hispanic	27 (84%)	33 (89%)	16 (73%)
Declined	2 (6%)	2 (5%)	3 (14%)
Race			
Asian	4 (11%)	4 (11%)	1 (5%)
Black	13 (41%)	10 (27%)	5 (23%)
White	11 (34%)	20 (54%)	11 (50%)
Other	3 (9%)	2 (5%)	1 (5%)
Declined	1 (3%)	1 (3%)	4 (18%)
History of Hypertension	26 (81%)	36 (97%)	2 (9%)
History of Diabetes Mellitus	9 (28%)	12 (32%)	0 (0%)
Years on PD	1.2 (0.6, 2.4)		
Automated Peritoneal Dialysis	21 (66%)		
Concurrent or Develops Future <i>Staphylococcus</i> Peritonitis	6 (19%)		
Decreased Donor Transplantation		14 (38%)	
Days Post Transplantation		364 (51, 1637)	
History of Prior Transplantation		4 (11%)	
Maintenance Immunosuppression			
Tacro/mycophenolic mofetil		19 (51%)	
Tacro/mycophenolic mofetil/pred		14 (38%)	
Tacro/mycophenolic acid		1 (3%)	
Tacro/mycophenolic acid/pred		3 (8%)	
Trimethoprim/Sulfamethoxazole PPx		12 (32%)	

422


423 **Demographics of the Cohort.** Categorical variables are represented by the number followed by the
424 percentage in parentheses. Continuous variables are represented by the median followed by the
425 interquartile range in parentheses.

TABLE 2

Genus	PD Cohort (n=32)	KTx Cohort (n = 37)	HC Cohort (n = 22)	PD vs. HC	PD vs. HC	PD vs. KTx	PD vs. KTx	KTx vs. HC	KTx vs. HC
	median abundance	median abundance	median abundance	P value	Adj P Value	P value	Adj P Value	P value	Adj P Value
<i>Anaerococcus</i>	0.020	0.004	0.014	0.999	0.999	0.238	0.722	0.303	0.389
<i>Corynebacterium</i>	0.098	0.200	0.127	0.509	0.573	0.271	0.722	0.701	0.701
<i>Cutibacterium</i>	0.000	0.000	0.009	0.016	0.049	0.942	0.942	0.029	0.133
<i>Finegoldia</i>	0.000	0.000	0.001	0.098	0.147	0.660	0.880	0.178	0.320
<i>Moraxella</i>	0.000	0.000	0.000	0.014	0.049	NA	NA	0.008	0.074
Unspecified									
<i>Neisseriaceae</i>	0.000	0.000	0.003	0.034	0.062	0.510	0.817	0.105	0.237
<i>Peptoniphilus</i>	0.000	0.000	0.013	0.022	0.049	0.382	0.763	0.046	0.139
<i>Staphylococcus</i>	0.249	0.403	0.257	0.406	0.522	0.891	0.942	0.285	0.389
<i>Streptococcus</i>	0.027	0.005	0.003	0.001	0.008	0.003	0.027	0.584	0.657


Comparison of the Nasal Abundance Among the 3 Cohorts at the Genus Level. The median abundance of the most common genera are shown for the peritoneal dialysis (PD) cohort, the kidney transplant cohort (KTx), and the living donor /healthy control (HC) cohort. P values shown were calculated using Wilcoxon rank sum test between groups. Adjusted P value (Adj P Value) were calculated using Benjamini-Hochberg adjustment. P values with NA were unable to be calculated because the abundances were 0 in both groups.

FIGURE 1



Distinct Differences in Nasal Microbial Diversity among the Study Cohort. Panel A shows box and whisker plots of Chao1 index, the estimated number of amplicon sequence variants, in the anterior nasal specimens from the peritoneal dialysis (PD) cohort, the kidney transplant cohort (KTx), and the living donor /healthy control (HC) cohort. The Chao1 index is on the y axis and the study group is on the x-axis. P value shown was calculated by Wilcoxon rank sum test. Panel B shows box and whisker plots of Shannon diversity index, a measure of evenness and richness, in the anterior nasal specimens from the 3 cohorts. The Shannon diversity index is on the y axis and the study group is on the x-axis. P values shown were calculated by Wilcoxon rank sum test.


FIGURE 2



Significant Correlations among the Most Common Genera in the Study Cohort. Panel A shows the most common genera in the anterior nasal microbiota (>1% mean relative abundance in the cohort). Box and whisker plots are represented to show the variation in the relative abundance of the genus (y-axis) with the genus on the x-axis. **Panel B** shows a correlational


matrix between the nasal abundance of the most common genera using Pearson's r correlations with Benjamini-Hochberg adjustment for multiple hypotheses. The numbers shown are Pearson's r correlations that had an adjusted P value < 0.10. The color shows the strength of the correlation with red showing a positive correlation between two genera and blue showing a negative correlation between two genera.

FIGURE 3




Individual Microbiota Profiles by the Study Cohort. The relative abundance of microbiota is on the y axis and individual nasal specimens are on the x-axis. The relative abundance of each genus is represented by color. The top panel represents anterior nasal microbiota profiles from the 32 peritoneal dialysis (PD) patients, the middle panel represents the anterior nasal microbiota profiles from the 37 kidney transplant (KTx) patients, and the bottom panel represents the anterior nasal microbiota profiles from the 22 potential living donor / healthy control (HC) participants. The right panel represents the microbiota from 3 negative controls.

FIGURE 4



Distinct microbial differences among the cohort at the genus level. Box and whisker plots are represented with the relative abundance of individual genera on the y axis and the group on the x axis. PD, peritoneal dialysis cohort (n=32). KTx, kidney transplant cohort (n=37). HC, living donor / healthy control cohort (n=22). P values were calculated using Wilcoxon rank sum testing with Benjamini-Hochberg adjustment for multiple hypothesis. ** Adjusted P value < 0.05 * Adjusted P value < 0.10. **Panel A**, *Staphylococcus* analysis. **Panel B**, *Corynebacterium* analysis. **Panel C**, *Anaerococcus* analysis. **Panel D**, *Streptococcus* analysis. **Panel E**, Unspecified *Neisseriaceae* analysis. **Panel F**, *Moraxella* analysis. **Panel G**, *Cutibacterium* analysis. **Panel H**, *Peptoniphilus* analysis. **Panel I**, *Finegoldia* analysis.


FIGURE 5



Differential abundance analyses among the cohort at the amplicon sequence variant level.

Differential abundance analyses were performed on the anterior nasal microbiota between the groups using DESeq2 with Benjamini-Hochberg adjustment for multiple hypothesis testing. On the y axis is the individual amplicon sequence variant with genus shown and on the x axis is the fold difference in abundance. PD, peritoneal dialysis cohort. KTx, kidney transplant cohort. HC, living donor / healthy control cohort. The fold difference directionality is represented above the graph. **Panel A** represents differential abundance analyses between the HC Group and the PD Group. **Panel B** represents differential abundance analyses between the KTx Group and the PD Group. **Panel C** represents differential abundance analyses between the HC Group and the KTx Group.

FIGURE 6



Diverse representation of the most common genera in the study cohort. Each set of graphs represents the number of amplicon sequence variant (ASV) from a particular genus by group. PD, peritoneal dialysis group (n=32). KTx, kidney transplant group (n=37). HC, living donor / healthy control group (n=22). The top graph presents box and whisker plots of the number of ASVs per specimen by group. P value was calculated using Wilcoxon rank sum test: ** P value < 0.05 * P value < 0.10. The bottom 3 graphs represent box and whisker plots of the relative abundance of individual ASVs from a particular genus. The relative abundance is on the y axis with the color representing individual ASVs and anterior nasal specimens are on the x axis with the second top graph representing the PD Cohort, the second bottom graph representing the KTx Cohort, and the bottom graph representing the HC Cohort. **Panel A** shows the diversity of *Staphylococcus* ASVs in the study cohort. **Panel B** shows the diversity of *Corynebacterium* ASVs in the study cohort. **Panel C** shows the diversity of *Streptococcus* ASVs in the study cohort.

SI Table 1

<i>Genus</i>	ASV	Base Mean	log ₂ Fold Change	Standard error	Wald stat	P value	Adj P value
<i>Finegoldia ASV #1</i>	1f016ec26e4774c86f029301b556de28	24.3	-26.4	2.9	-9.0	3.4E-19	1.4E-17
<i>Anaerococcus ASV #1</i>	ae7cf0f32080cf5e62b3fbd903a997af	16.5	-25.9	3.0	-8.7	2.2E-18	4.4E-17
<i>Lawsonella ASV #1</i>	b89dbfe5c74375ff3d4922b41c470740	49.0	-7.3	2.9	-2.5	1.3E-02	5.1E-02
<i>Corynebacterium ASV #2</i>	c91b64f1467982a81922d331a310f5dc	1172.2	-3.7	1.6	-2.2	2.5E-02	9.2E-02
<i>Bacillus ASV #1</i>	5565e52f91bc244013249656795409ca	18.7	6.9	1.8	3.8	1.7E-04	7.7E-04
<i>Staphylococcus ASV #2</i>	b273d7d05f0525bb87418b0138d90605	86.0	11.8	2.2	5.3	1.2E-07	6.1E-07
<i>Porphyromonas ASV #1</i>	969732ae717bf5a9282f4781499aadb4	10.0	21.4	3.0	7.2	6.3E-13	3.6E-12
<i>Abitrophia ASV #1</i>	afce1dc2c06acb90ad5d3da0fffbcd02	9.7	22.3	2.8	7.9	3.5E-15	2.4E-14
<i>Streptococcus ASV #1</i>	4481bc66d3a54f79e6abb8b557a2a104	19.3	23.2	2.9	7.9	2.5E-15	2.4E-14
<i>Staphylococcus ASV #1</i>	7b06c22a4ff85c9b2cbbf57a53462e13	41.9	23.4	3.0	7.9	3.6E-15	2.4E-14
<i>Corynebacterium ASV #1</i>	0560198302010f9b110d4ec9897e14d0	45.9	24.5	3.0	8.2	1.8E-16	2.3E-15

DESeq2 Analysis of the Nasal Microbiota between the PD Group and the HC Group. The listed ASV were determined to be significantly different using an adjusted p value of 0.10. Base Mean, mean of normalized counts for all samples. Wald stat, Wald statistic. Positive log₂ Fold Change is higher in the PD Group.

SI Table 2

<i>Genus</i>	ASV	Base Mean	log2 Fold Change	Standard error	Wald stat	P value	Adj P value
<i>Staphylococcus ASV #3</i>	0f89ba63b47f3b624c13293cb4d56486	16.5	-25.6	2.9	-8.8	1.9E-18	2.0E-16
<i>Porphyromonas ASV #1</i>	969732ae717bf5a9282f4781499aadb4	7.4	21.6	2.9	7.4	1.1E-13	4.8E-12
<i>Abitrophia ASV #1</i>	afce1dc2c06acb90ad5d3da0fffbcd02	7.3	23.3	2.8	8.4	4.3E-17	3.0E-15
<i>Corynebacterium ASV #3</i>	36f00e24a741c19a5ee20f58919004ad	12.4	24.0	2.9	8.2	1.7E-16	8.8E-15
<i>Staphylococcus ASV #2</i>	b273d7d05f0525bb87418b0138d90605	65.8	24.8	2.4	10.2	1.5E-24	3.1E-22

DESeq2 Analysis of the Nasal Microbiota between the PD Group and the KTx Group. The listed ASV were determined to be significantly different using an adjusted p value of 0.10. Base Mean, mean of normalized counts for all samples. Wald stat, Wald statistic. Positive log2 Fold Change is higher in the PD Group.

SI Table 3

<i>Genus</i>	ASV	Base Mean	log2 Fold Change	Standard error	Wald stat	P value	Adj P value
<i>Anaerococcus ASV #1</i>	ae7cf0f32080cf5e62b3fbd903a997af	12.0	-25.4	3.0	-8.5	2.8E-17	2.2E-15
<i>Corynebacterium ASV #4</i>	9f6c00ff9e1f455f42f211770d60dec0	11.2	-25.3	3.0	-8.4	3.6E-17	2.2E-15
<i>Staphylococcus ASV #3</i>	0f89ba63b47f3b624c13293cb4d56486	12.5	21.6	3.0	7.2	7.4E-13	2.8E-11
<i>Staphylococcus ASV #1</i>	7b06c22a4ff85c9b2cbbf57a53462e13	11.8	22.9	3.0	7.6	2.8E-14	1.3E-12
<i>Corynebacterium ASV #1</i>	0560198302010f9b110d4ec9897e14d0	237.4	27.1	3.0	9.0	2.2E-19	4.1E-17

DESeq2 Analysis of the Nasal Microbiota between the KTx Group and the HC Group. The listed ASV were determined to be significantly different using an adjusted p value of 0.10. Base Mean, mean of normalized counts for all samples. Wald stat, Wald statistic. Positive log2 Fold Change is higher in the KTx Group.

SI Table 4

Genus	Age \geq 65	Age < 65	P value	Adj P value
	n = 28	n = 63		
<i>Staphylococcus</i>	0.187	0.346	0.11	0.40
<i>Finegoldia</i>	0.000	0.001	0.11	0.40
<i>Anaerococcus</i>	0.001	0.013	0.14	0.40
<i>Moraxella</i>	0.000	0.000	0.18	0.40
<i>Unspecified Neisseriaceae</i>	0.000	0.000	0.30	0.48
<i>Streptococcus</i>	0.012	0.007	0.32	0.48
<i>Corynebacterium</i>	0.124	0.139	0.56	0.72
<i>Peptoniphilus</i>	0.000	0.000	0.66	0.74
<i>Cutibacterium</i>	0.003	0.002	0.81	0.81

Comparison of Nasal Microbiota Based on Patient's Age at the Genus Level. P value was calculated between groups using Wilcoxon rank sum test. Adjusted p value (Adj P value) was calculated using Benjamini-Hochberg adjustment.

SI Table 5

Genus	Female Sex	Male Sex	P value	Adj P value
	n = 50	n = 41		
	Median Abundance	Median Abundance		
<i>Peptoniphilus</i>	0.000	0.005	0.01	0.10
<i>Finegoldia</i>	0.000	0.002	0.07	0.31
<i>Anaerococcus</i>	0.002	0.017	0.19	0.51
<i>Corynebacterium</i>	0.101	0.197	0.23	0.51
<i>Cutibacterium</i>	0.002	0.007	0.38	0.64
<i>Moraxella</i>	0.000	0.000	0.43	0.64
Unspecified <i>Neisseriaceae</i>	0.000	0.000	0.90	0.91
<i>Streptococcus</i>	0.008	0.010	0.90	0.91
<i>Staphylococcus</i>	0.285	0.250	0.91	0.91

Comparison of Nasal Microbiota Based on Patient's Sex at the Genus Level. P value was calculated between groups using Wilcoxon rank sum test. Adjusted p value (Adj P value) was calculated using Benjamini-Hochberg adjustment.

SI Table 6

Genus	KTx on TMP/SMX	KTx off TMP/SMX	P value	Adj P value
	n = 12	n = 25		
	Median Abundance	Median Abundance		
<i>Finegoldia</i>	0.000	0.002	0.02	0.15
<i>Peptoniphilus</i>	0.000	0.000	0.04	0.15
<i>Anaerococcus</i>	0.0002	0.007	0.06	0.15
<i>Corynebacterium</i>	0.101	0.314	0.36	0.59
<i>Cutibacterium</i>	0.000	0.000	0.37	0.59
<i>Staphylococcus</i>	0.363	0.487	0.53	0.71
Unspecified <i>Neisseriaceae</i>	0.000	0.000	0.70	0.80
<i>Streptococcus</i>	0.002	0.005	0.84	0.84
<i>Moraxella</i>	0.000	0.000	NA	NA

Comparison of Nasal Microbiota Based on Trimethoprim/Sulfamethoxazole usage in the Kidney Transplant Recipients at the Genus Level. P value was calculated between groups using Wilcoxon rank sum test. Adjusted p value (Adj P value) was calculated using Benjamini-Hochberg adjustment. P values with NA were unable to be calculated because the abundances were 0 in both groups. KTx, Kidney Transplant; TMP/SMX, trimethoprim/sulfamethoxazole.

SI Table 7

Genus	PD Staph	PD No Staph	P value	Adj P value
	Future Peritonitis n = 6	Future Peritonitis n = 26		
	Median Abundance	Median Abundance		
Unspecified <i>Neisseriaceae</i>	0.000	0.000	0.08	0.66
<i>Staphylococcus</i>	0.521	0.240	0.38	0.73
<i>Streptococcus</i>	0.009	0.035	0.38	0.73
<i>Anaerococcus</i>	0.0002	0.022	0.39	0.73
<i>Peptoniphilus</i>	0.000	0.000	0.48	0.73
<i>Cutibacterium</i>	0.001	0.000	0.55	0.73
<i>Finegoldia</i>	0.000	0.000	0.76	0.87
<i>Corynebacterium</i>	0.101	0.098	1.00	1.00
<i>Moraxella</i>	0.000	0.000	NA	NA

Comparison of Nasal Microbiota Based on PD patients who developed *Staphylococcus* peritonitis status and PD patients who did not develop *Staphylococcus* peritonitis at the Genus Level. P value was calculated between groups using Wilcoxon rank sum test. Adjusted p value (Adj P value) was calculated using Benjamini-Hochberg adjustment. P values with NA were unable to be calculated because the abundances were 0 in both groups. PD Staph peritonitis cohort was defined as PD patients who currently had *Staphylococcus* peritonitis or developed *Staphylococcus* peritonitis within 10 to 12 months (last follow up).